Trial
NCT04365400
Assess Efficacy and Safety of Epeleuton in Patients With Hypertriglyceridemia and Type 2 Diabetes
Phase IITERMINATEDEFFICACY/FUTILITYConfidence: HIGH
Sponsor
Afimmune
Collaborators
—
Condition
Hypertriglyceridemia
Intervention
DS102
Why stopped
Trial prematurely terminated on 03 May 2022 due to the results from an interim analysis indicating a lack of efficacy in the study population.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2023-06-12